HeartBeam

HeartBeam, Inc. is a development stage company, which engages in cardiovascular diagnostic technology. Its electrocardiogram (ECG) collection device provides physicians with cardiac diagnostic information for a patient that is outside of a medical institution. The device sends ECG signals to the patient's smartphone and on to a cloud-based software expert system. The company was founded by Branislav Vajdic in 2015 and is headquartered in Santa Clara, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

HeartBeam reports Q1 loss, eyes FDA clearances for growth

HeartBeam's Q1 2024 performance showed financial challenges but promising technological advancements
The company's focus on FDA clearances and AI development positions it for growth
Opportunities in remote cardiac monitoring and AI-driven healthcare present avenues for expansion
Balancing financial stability with innovation will be key for HeartBeam's future success

HeartBeam advances AIMIGo technology despite financial challenges

HeartBeam is making progress towards FDA clearance for its innovative cardiac monitoring device, AIMIGo.
Despite financial challenges, the company's strong IP protection and AI capabilities position it well for future growth.
Opportunities lie in expanding technology applications, gaining regulatory approval, and leveraging AI for automated diagnostics.

HeartBeam reports Q3 loss, progresses FDA review, and strengthens leadership

HeartBeam's Q3 2024 financials show a net loss of $4.979 million, with a focus on managing cash burn and aligning capital raising with milestones.
The company's core technology and clinical evidence position it well for FDA clearances and commercial launch preparations.
New management appointments bring leadership strength to drive HeartBeam's growth and innovation in cardiac care.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HeartBeam, Inc. (NASDAQ:BEAT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Rob Eno - Chief Executive Officer Branislav Vajdic - President and Founder Tim Cruickshank - Chief Financial Officer Conference Call Participants Operator Greetings, and welcome to the HeartBeam Third Quarter 2024 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.

HeartBeam, Inc. (BEAT) Q3 2024 Earnings Call Transcript

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Reports Third Quarter 2024 Results.

HeartBeam Reports Third Quarter 2024 Results

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host Third Quarter 2024 Results Conference Call on Thursday, November 7, 2024 at 4:30 p.m. Eastern Time.

HeartBeam to Host Third Quarter 2024 Results Conference Call on Thursday, November 7, 2024 at 4:30 p.m. Eastern Time

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Named “Rising Star” at the 6th Annual Digital Health Hub Foundation Awards.

HeartBeam Named “Rising Star” at the 6th Annual Digital Health Hub Foundation Awards

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Appoints Robert Eno as Chief Executive Officer in Preparation for US Commercialization.

HeartBeam Appoints Robert Eno as Chief Executive Officer in Preparation for US Commercialization

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Appoints Dr. Lance Myers as Chief AI Scientist.

HeartBeam Appoints Dr. Lance Myers as Chief AI Scientist

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Names Timothy Cruickshank as Chief Financial Officer.

HeartBeam Names Timothy Cruickshank as Chief Financial Officer

HeartBeam, Inc. (NASDAQ:BEAT ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Branislav Vajdic - Founder and CEO Rob Eno - President Ravi Malhotra - Senior Director, Corporate Controller Conference Call Participants Operator Greetings, and welcome to the HeartBeam Second Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

HeartBeam, Inc. (BEAT) Q2 2024 Earnings Call Transcript

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Reports Second Quarter 2024 Results.

HeartBeam Reports Second Quarter 2024 Results

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host Second Quarter 2024 Results Conference Call on Wednesday, August 14, 2024 at 4:30 p.m. Eastern Time.

HeartBeam to Host Second Quarter 2024 Results Conference Call on Wednesday, August 14, 2024 at 4:30 p.m. Eastern Time

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Added to Russell Microcap® Index.

HeartBeam Added to Russell Microcap® Index

SALT LAKE CITY--(BUSINESS WIRE)--Epitel, a leader in AI technologies for patient-focused brain health solutions, announced today the addition of wearables industry pioneer Ken Nelson to its Board of Directors. With his extensive experience in digital health, medical devices, and remote patient monitoring, Nelson will play a crucial role in guiding Epitel's growth as the company continues to transform the landscape of brain monitoring through AI/ML and its wearable EEG technology. Ken Nelson bri.

Epitel Announces Appointment of Wearables Industry Leader Ken Nelson to Board of Directors

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam's Artificial Intelligence Algorithm Combined with Vectorcardiography (VCG) Outperforms Expert Cardiologists in Detecting Arrhythmias.

HeartBeam's Artificial Intelligence Algorithm Combined with Vectorcardiography (VCG) Outperforms Expert Cardiologists in Detecting Arrhythmias

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam AIMIGo™ Recognized for Digital Health Innovation in 8th Annual MedTech Breakthrough Awards Program.

HeartBeam AIMIGo™ Recognized for Digital Health Innovation in 8th Annual MedTech Breakthrough Awards Program

HeartBeam, Inc. (NASDAQ:BEAT ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Branislav Vajdic - Founder and CEO Rob Eno - President Rick Brounstein - Consulting Chief Financial Officer Brooks Hamilton - Investor Relations, MZ Group Conference Call Participants Leo Carpio - Joseph Gunnar Operator Greetings. And welcome to the HeartBeam First Quarter 2024 Financial Results Conference Call.

HeartBeam, Inc. (BEAT) Q1 2024 Earnings Call Transcript

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Reports First Quarter 2024 Results.

HeartBeam Reports First Quarter 2024 Results

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host First Quarter 2023 Results Conference Call on Thursday May 9, 2024 at 4:30 p.m. Eastern Time.

HeartBeam to Host First Quarter 2023 Results Conference Call on Thursday May 9, 2024 at 4:30 p.m. Eastern Time

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Presents Positive Results on its Artificial Intelligence Capabilities for Detecting Arrhythmias.

HeartBeam Presents Positive Results on its Artificial Intelligence Capabilities for Detecting Arrhythmias

HeartBeam (NASDAQ: BEAT ) just reported results for the fourth quarter of 2023. HeartBeam reported earnings per share of -13 cents.

BEAT Stock Earnings: HeartBeam Meets EPS for Q4 2023

HeartBeam, Inc. (BEAT) Q4 2023 Earnings Call Transcript

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Reports Fourth Quarter and Full Year 2023 Financial Results.

HeartBeam Reports Fourth Quarter and Full Year 2023 Financial Results

SANTA CLARA, Calif.--(BUSINESS WIRE)--First Patients Enrolled in Pivotal Study Evaluating HeartBeam's AIMIGo™ System for Synthesizing a 12-Lead ECG.

First Patients Enrolled in Pivotal Study Evaluating HeartBeam's AIMIGo™ System for Synthesizing a 12-Lead ECG

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Receives Two New US Patents for its Core Cardiac Monitoring Technology.

HeartBeam Receives Two New US Patents for its Core Cardiac Monitoring Technology

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host Fourth Quarter and Full Year 2023 Results Conference Call on Wednesday March 20, 2024 at 4:30 p.m. Eastern Time.

HeartBeam to Host Fourth Quarter and Full Year 2023 Results Conference Call on Wednesday March 20, 2024 at 4:30 p.m. Eastern Time

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Unveils AI Program Designed to Deliver Unprecedented Personalized Cardiac Insights.

News for HeartBeam Stock (BEAT)